Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Leoclan CoTSE:7681 66 Return-on-Tangible-Equity is 10.85% as of Mar. 2026, which is 33% above its 10-year median of 8.18. GuruFocus rates TSE:7681 with a GF Score™ of 66/100 and a GF Value™ of 円1,290.91 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 111 Medical Distribution companies, Leoclan Co ranks worse than 79.28% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Leoclan Co's annualized net income for the quarter that ended in Mar. 2026 was 円472 Mil. Leoclan Co's average shareholder tangible equity for the quarter that ended in Mar. 2026 was 円4,345 Mil. Therefore, Leoclan Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 10.85%.
The historical rank and industry rank for Leoclan Co's Return-on-Tangible-Equity or its related term are showing as below:
TSE:7681'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 0.92 Med: 8.18 Max: 19.1
Current: 0.92
During the past 9 years, Leoclan Co's highest Return-on-Tangible-Equity was 19.10%. The lowest was 0.92%. And the median was 8.18%.
TSE:7681's Return-on-Tangible-Equity is ranked worse than 79.28% of 111
companies
in the Medical Distribution industry
Industry Median: 8.78
vs TSE:7681: 0.92
Leoclan Co (TSE:7681) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Leoclan Co Return-on-Tangible-Equity Related Terms
Leoclan Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Leoclan Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7681 vs MCK, COR, CAH: Return-on-Tangible-Equity Comparison
For the Medical Distribution subindustry, Leoclan Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Leoclan Co Return-on-Tangible-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Leoclan Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Leoclan Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 10.85% mean?
Leoclan Co (TSE:7681) has a Return-on-Tangible-Equity of 10.85% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Leoclan Co and its competitors. This is 33% above median its historical median of 8.18. Over the past decade, Leoclan Co's Return-on-Tangible-Equity has ranged from 0.92 to 19.10. According to the industry distribution chart, Leoclan Co ranks #88 out of 111 companies in the Medical Distribution industry, placing it in the top 79.3%.
Is Leoclan Co's Return-on-Tangible-Equity too high?
Leoclan Co's current Return-on-Tangible-Equity of 10.85% is 33% above median its 10-year median of 8.18. Over the past 10 years, this metric has ranged from a low of 0.92 to a high of 19.10. The Medical Distribution industry median Return-on-Tangible-Equity is 8.78. Leoclan Co's value of 10.85% is 23.6% above this industry median. Based on the distribution chart, Leoclan Co ranks #88 out of 111 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Leoclan Co has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Leoclan Co's Return-on-Tangible-Equity compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Leoclan Co ranks #88 out of 111 companies for Return-on-Tangible-Equity. This places Leoclan Co in the lower half of its industry. The industry median Return-on-Tangible-Equity is 8.78. Leoclan Co's value of 10.85% is 23.6% above this benchmark. Historically, Leoclan Co's own Return-on-Tangible-Equity has ranged from 0.92 to 19.10 over the past decade. While the company's 10-year median is 8.18 vs. the industry median of 8.78, Leoclan Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Distribution company?
The median Return-on-Tangible-Equity among Medical Distribution companies is 8.78, based on 111 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Leoclan Co's current Return-on-Tangible-Equity of 10.85% is 23.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Leoclan Co and its competitors. For the Medical Distribution industry, the median Return-on-Tangible-Equity is 8.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Leoclan Co's current Return-on-Tangible-Equity is 10.85%, which is 33% above median its own 10-year median of 8.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Leoclan Co stock overvalued right now?
Based on GuruFocus' analysis, Leoclan Co (TSE:7681) is currently considered Modestly Undervalued. The stock's GF Value™ is 円1,290.91, compared to a current price of 円955.00 — trading 26% below its estimated fair value. The current Return-on-Tangible-Equity is 10.85%, which is 33% above median its 10-year median of 8.18 and 23.6% above the Medical Distribution industry median of 8.78. Leoclan Co's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Leoclan Co (TSE:7681), the current Return-on-Tangible-Equity is 10.85% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Leoclan Co (TSE:7681) Overvalued in 2026?
Based on GuruFocus' analysis, Leoclan Co stock appears to be undervalued.
The current stock price of 円955.00 is trading 26% below its estimated GF Value™ of 円1,290.91.
GuruFocus considers Leoclan Co to be Modestly Undervalued.
Key valuation signals for TSE:7681:
Return-on-Tangible-Equity: 10.85% (33% above median its 10-year median of 8.18)
GF Value™: 円1,290.91 vs. price of 円955.00 (26% below fair value)
Industry Position: 23.6% above the Medical Distribution median (#88 of 111)
No single metric tells the full story. See the TSE:7681 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7681 has been successfully added to your 
